Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IL-2 and Tebentafusp in Metastatic Uveal Melanoma
NCT07063875Phase 2Recruiting
- Sponsor
- St Vincent's Hospital
- Start
- Jun 2025
- Primary completion
- Sep 2027
- Modality
- Cytokines & Interferons
- Countries
- 1
01
Overview
A Phase 2 trial of aldesleukin in Uveal melanoma (UM), sponsored by St Vincent's Hospital. Started Jun 2025; status: recruiting.
02
Drugs
aldesleukin
03
Conditions
Uveal melanoma (UM)
Beyond the preview
Go deeper on NCT07063875.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07063875.